

Inventors: GLENN et al.

Appln. No.: 09

257,188

Series Code ↑

Serial No. ↑

Filed: May 14, 1999

Hon. Commissioner of Patents

Washington, D.C. 20231

Group Art Unit 1644

Examiner: G. Ewoldt

Atty. Dkt. PW 244954

1002

M#

Client Ref.

Appln. Title: USE OF PENETRATION ENHANCERS  
AND BARRIER DISRUPTION AGENTS  
TO ENHANCE TRANSCUTANEOUS  
IMMUNE RESPONSE ...

Sir:

**RESPONSE TO RESTRICTION REQUIREMENT**

Date: July 20, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

**FEE REQUIREMENTS FOR CLAIMS AS AMENDED**

## 1. Small Entity claim

- A. ☒ NOT made  
B. ☐ Withdrawn  
C. ☐ made herewith  
D. ☐ made previously
- For B & C  
See Required  
Separate Paper  
(Pat-256)

| Claims remaining after amendment   | Highest number previously paid for | Present Extra  | Large/Small Entity | Additional Fee      | Fee Code Lg/Sm                                      |
|--|------------------------------------|--|--------------------|---------------------|---|
| 2. Total Effective Claims  | 59                                 | **minus 59   | 0                  | x \$18/\$9 = + \$0  | 103/203   |
| 3. Independent Claims  | 8                                  | ***minus 8   | 0                  | x \$80/\$40 = + \$0 | 102/202   |
| 4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) .....  |                                    | add  | + \$270/\$135 =    | + \$0               | 104/204   |
| 5. Original due Date: April 20, 2001   | <input type="checkbox"/> NONE      |  |                    |                     |   |
| 6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached<br>(Usable only for ≤ 2mo.OA --- 4 mos)<br>(Usable only for 30 day/1mo.OA --- 5 mos) | (1 mo)<br>(2 mos)<br>(3 mos)       | \$110/\$55 =<br>\$390/\$195 =<br>\$890/\$445 =<br>\$1390/\$695 =<br>\$1890/\$945 = | + \$890            |                     | 115/215<br>116/216<br>117/217<br>118/218<br>128/228 |
| 7. Enter any previous extension fee paid since above original due date and subtract  |                                    |  | - \$0              |                     |   |
| 8. Extension Fee Attached  |                                    |  | + \$890            |                     |   |
| 9. If Terminal Disclaimer attached, add Rule 20(d) official fee .....  |                                    |  | + \$110/\$55       | + \$0               | 148/248   |
| 10. If IDS attached requires Official Fee under Rule 97 (c) .....  | add                                |  | + \$180            | + \$0               | 126   |
| or if Rule 97(d) Request .....   | add                                |  | + \$180            |                     | 126   |
| 11. After-Final Request Fee per rules 129(a) and 17(r) .....   |                                    |  | + \$710/355        | + \$0               | 146/246   |
| 12. No. of additional inventions for examination per Rule 129(b) .....   |                                    |  | x \$710/355 ea     | + \$0               | 149/249   |
| 13. Request for Continued Examination (RCE) .....  |                                    |  | + \$710/355        | + \$0               | 1179/1279   |
| 14. Petition fee for .....   |                                    |  |                    | + \$0               |   |

TOTAL FEE ENCLOSED = \$890

15.

16. \*If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975

Our Order No. 081255

C#

0244954

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.


This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP  
Intellectual Property Group

By Atty: Gary R. Tanigawa

Sig:



Reg. No. 43180

Fax: (703) 905-2500

Tel: (703) 905-2196

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Atty/Sec: GRT/nlh

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

GLENN et al.

Appln. No. 09/257,188

Filed: February 25, 1999

FOR: USE OF PENETRATION ENHANCERS AND BARRIER DISRUPTION  
AGENTS TO ENHANCE THE TRANSCUTANEOUS IMMUNE RESPONSE  
INDUCED BY ADP-RIBOSYLATING EXOTOXIN



#11/8  
VC  
8/1-1  
RECEIVED

JUL 27 2001

TECH CENTER 1600/2900  
Group Art Unit: 1644

Examiner: G. Ewoldt

\* \* \* \*

July 20, 2001

**PRELIMINARY AMENDMENT AND RESPONSE TO RESTRICTION  
REQUIREMENT**

Hon. Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action of March 20, 2001 (Paper No. 10), entry and consideration of the following amendments and remarks are requested.

**IN THE SPECIFICATION:**

Kindly enter the following amended paragraph.

Page 1, replace the first paragraph claiming priority to provisional applications with the following paragraph:

**CROSS-REFERENCE TO RELATED APPLICATIONS**

31  
This application is a continuation in-part of U.S. Appln. No. 08/749,164 (filed November 14, 1996; U.S. Patent No. 5,910,306); U.S. Appln. No. 08/896,085 (filed July 17, 1997; U.S. Patent No. 5,980,898); and PCT/US97/21324 designating the U.S. (filed November 14, 1997; now abandoned). This application claims the benefit of provisional U.S. Appln. No. 60/075,856 (filed February 25, 1998); U.S. Appln. No. 60/075,850 (filed February 25, 1998); and U.S. Appln. No. 60/086,251 (filed May 21, 1998).